Raymond James Financial Services Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-739	Closed	-$3.4K	–	3310
2023 Q2	$3.4K	Hold	739	–	–	﹤0.01%	3230
2023 Q1	$5.24K	Sell	739 -100	-12%	-$742	﹤0.01%	3242
2022 Q4	$5.38K	Hold	839	–	–	﹤0.01%	3215
2022 Q3	$12K	Hold	839	–	–	﹤0.01%	3201
2022 Q2	$15K	Hold	839	–	–	﹤0.01%	3185
2022 Q1	$25K	Buy	+839	New	+$26.8K	﹤0.01%	3248
2021 Q4	–	Sell	-787	Closed	-$56K	–	3404
2021 Q3	$56K	Buy	+787	New	+$72.3K	﹤0.01%	3181

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raymond James Financial Services Advisors's IMDX Position: Q3 2023 in Review

Raymond James Financial Services Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 739 shares — an estimated $3.4K sold.

Raymond James Financial Services Advisors first reported a position in IMDX in Q3 2021 and held it in 7 quarters. The position peaked at $56K in Q3 2021. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

Raymond James Financial Services Advisors reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 739 Insight Molecular Diagnostics shares in Q3 2023, an estimated $3.4K.
Raymond James Financial Services Advisors first reported a position in Insight Molecular Diagnostics in Q3 2021 and held it in 7 quarters.
Raymond James Financial Services Advisors's Insight Molecular Diagnostics position peaked at $56K in Q3 2021.
30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.